{"protocolSection":{"identificationModule":{"nctId":"NCT05531461","orgStudyIdInfo":{"id":"COGNITIVE Study"},"organization":{"fullName":"Rapid Medical","class":"INDUSTRY"},"briefTitle":"Cognition and Imaging With Tigertriever","officialTitle":"COGNITIVE Study- Cognition and Imaging With Tigertriever","acronym":"COGNITIVE"},"statusModule":{"statusVerifiedDate":"2023-03","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-06","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-11","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-11","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-09-04","studyFirstSubmitQcDate":"2022-09-04","studyFirstPostDateStruct":{"date":"2022-09-08","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-03-28","lastUpdatePostDateStruct":{"date":"2023-03-29","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Rapid Medical","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The objective of the COGNITIVE Study is to evaluate whether successful reperfusion with Tigertriever is associated with cognitive benefit."},"conditionsModule":{"conditions":["Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":true,"targetDuration":"1 Year","designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":424,"type":"ESTIMATED"}},"outcomesModule":{"primaryOutcomes":[{"measure":"Association between successful reperfusion* and cognitive benefit**","description":"\\*successful reperfusion is defined as eTICI ≥2b50 with the Tigertriever device.\n\n* Cognitive benefit is defined as change in Montreal Cognitive Assessment (MoCA) of 1.5 Standard Deviations (SD) from 4 days post treatment (or discharge if earlier) and 180 days post treatment; or MoCA ≥26 at 180 days post treatment.","timeFrame":"180 days post treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients admitted with large vessel occlusion (LVO) and treated with the Tigertriever, as indicated per the approved IFU.\n2. Tigertriever was used as the first line treatment in the target vessel.\n3. A signed informed consent.\n4. Age 18-75 years (inclusive).\n5. No known significant pre-stroke disability (pre-stroke mRS 0 or 1).\n\nExclusion Criteria:\n\n1. Use of any other IA recanalization device prior to the Tigertriever in the target vessel, including aspiration catheter.\n2. Evidence of acute brain hemorrhage on CT and/or MRI at admission.\n3. Prior hemorrhage, stroke, thrombolysis, and/or endovascular therapy in the last 3 months.\n4. Probable cerebral amyloid angiopathy.\n5. Pre-stroke diagnosed dementia and/or prescribed cholinesterase inhibitors.\n6. Pre-stroke diagnosed and/or currently treated major depression.\n7. Pre-stroke learning or intellectual disability.\n8. Anticipated inability to obtain 6-month follow-up assessments.\n\n   -","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"The COGNITIVE Study will include male or female subjects age 18-75 who present with LVO and treated with the Tigertriever as indicated per approved IFU.","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Walid Haddad, Dr.","role":"CONTACT","phone":"+972 72 2503331","email":"walid@rapid-medical.com"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"}]}},"hasResults":false}